Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Key facts
- Who runs it
- Hospital de Clinicas de Porto Alegre
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 600 people, planned
- Started
- Feb 2002
- Expected to end
- Dec 2032
- Type of study
- Interventional
- Treatments tested
- Immediate-release Methylphenidate
- Record updated
- 1 November 2016
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- White Brazilian of European descent
- Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
- Eligibility to immediate-release MPH (IR-MPH) treatment
Who cannot take part
- Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
- Current or past history of psychosis
- Contraindication for IR-MPH use
- Current stimulant treatment
- Estimated intelligence quotient score lower than 70
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Attention deficit disorder with hyperactivity
This trial is currently available in Brazil.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
The group in the trial
- IR-MPHTreatment being tested
Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
Treatment: Immediate-release Methylphenidate
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT02951754, who can take part
- Record updated
- 1 November 2016